The average one-year price target for Palisade Bio (NasdaqCM:PALI) has been revised to $11.90 / share. This is an increase of 45.83% from the prior estimate of $8.16 dated November 7, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $22.05 / share. The average price target represents an increase of 456.08% from the latest reported closing price of $2.14 / share.
What is the Fund Sentiment?
There are 23 funds or institutions reporting positions in Palisade Bio. This is an increase of 8 owner(s) or 53.33% in the last quarter. Average portfolio weight of all funds dedicated to PALI is 0.00%, an increase of 107.46%. Total shares owned by institutions increased in the last three months by 43.13% to 149K shares.
What are Other Shareholders Doing?
Two Sigma Securities holds 29K shares representing 0.02% ownership of the company. In its prior filing, the firm reported owning 16K shares , representing an increase of 45.69%. The firm increased its portfolio allocation in PALI by 178.31% over the last quarter.
Geode Capital Management holds 27K shares representing 0.02% ownership of the company. In its prior filing, the firm reported owning 25K shares , representing an increase of 7.09%. The firm decreased its portfolio allocation in PALI by 34.22% over the last quarter.
UBS Group holds 19K shares representing 0.01% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 98.29%. The firm increased its portfolio allocation in PALI by 1,125.92% over the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 19K shares representing 0.01% ownership of the company. In its prior filing, the firm reported owning 6K shares , representing an increase of 66.52%. The firm increased its portfolio allocation in PALI by 180.38% over the last quarter.
XTX Topco holds 14K shares representing 0.01% ownership of the company. In its prior filing, the firm reported owning 27K shares , representing a decrease of 94.09%. The firm decreased its portfolio allocation in PALI by 18.48% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
